Emily M. Leproust Sells 4,163 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 4,163 shares of the company’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $37.13, for a total value of $154,572.19. Following the completion of the sale, the chief executive officer now owns 509,986 shares in the company, valued at approximately $18,935,780.18. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Twist Bioscience Stock Down 4.0 %

Shares of Twist Bioscience stock opened at $41.40 on Thursday. The company has a 50 day moving average price of $34.18 and a 200 day moving average price of $31.59. Twist Bioscience Co. has a 52 week low of $11.81 and a 52 week high of $44.92. The firm has a market capitalization of $2.41 billion, a P/E ratio of -12.32 and a beta of 1.64.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.05. The business had revenue of $75.30 million during the quarter, compared to analyst estimates of $70.70 million. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The business’s revenue was up 25.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.06) earnings per share. As a group, research analysts anticipate that Twist Bioscience Co. will post -3.17 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on TWST. The Goldman Sachs Group upgraded shares of Twist Bioscience from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $25.00 to $45.00 in a report on Wednesday, January 17th. Scotiabank increased their target price on shares of Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a report on Monday. Robert W. Baird lifted their price objective on Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Evercore ISI lifted their target price on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Finally, Barclays increased their price target on Twist Bioscience from $40.00 to $45.00 and gave the stock an “overweight” rating in a research note on Friday, May 3rd. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $42.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. ARK Investment Management LLC grew its stake in Twist Bioscience by 6.3% during the 4th quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock worth $265,881,000 after buying an additional 427,274 shares during the last quarter. Artisan Partners Limited Partnership increased its stake in shares of Twist Bioscience by 111.3% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock worth $137,241,000 after acquiring an additional 1,961,621 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in Twist Bioscience by 2.9% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,583,443 shares of the company’s stock worth $132,086,000 after purchasing an additional 99,511 shares in the last quarter. Nikko Asset Management Americas Inc. boosted its holdings in Twist Bioscience by 2.9% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company’s stock valued at $131,835,000 after purchasing an additional 99,511 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Twist Bioscience by 29.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock worth $46,732,000 after purchasing an additional 284,884 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.